Low adenosine anti-sense oligonucleotide, compositions, kit...

Details Low adenosine anti-sense oligonucleotide, compositions, kit... Low adenosine anti-sense oligonucleotide, compositions, kit...

2006-04-25

2006-04-25

LeGuyader, John L. (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S006120, C435S325000, C435S375000, C536S024300, C536S024310, C536S024330, C536S024500

Reexamination Certificate

active

07034007

ABSTRACT:
An in vivo method of selectively delivering a nucleic acid to a target gene or mRNA, comprises the topical administration, e.g. to the respiratory system, of a subject of a therapeutic amount of an oligonucleotide (oligo) that is anti-sense to a mRNA complementary to the gene in an amount effective to reach the target polynucleotide and reducing or inhibiting expression. The composition and formulations are used for prophylactic, preventive and therapeutic treatment of ailments associated with impaired respiration, lung allergy(ies) and/or inflammation and depletion lung surfactant or surfactant hypoproduction, such as pulmonary vasoconstriction, inflammation, allergies, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction. The treatment of this invention may be administered directly into the respiratory system of a subject so that the agent has direct access to the lungs, in an amount effective to reduce or inhibit the symptoms of the ailment.

REFERENCES:
patent: 5225326 (1993-07-01), Bresser et al.
patent: 5245022 (1993-09-01), Weis et al.
patent: 5320962 (1994-06-01), Stiles et al.
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5646156 (1997-07-01), Jacobson et al.
patent: 5858981 (1999-01-01), Schreiber et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 2264948 (1993-09-01), None
patent: 9310820 (1993-06-01), None
patent: 9312756 (1993-07-01), None
patent: WO 93/25677 (1993-12-01), None
patent: 9402605 (1994-02-01), None
patent: WO 94/02605 (1994-03-01), None
patent: 9640162 (1996-12-01), None
patent: 9640266 (1996-12-01), None
patent: 9811211 (1998-03-01), None
patent: 9823294 (1998-06-01), None
patent: 9960166 (1999-11-01), None
patent: 0009525 (2000-02-01), None
Mouse endogenouse murine leukemia mink cell focus-forming (MCF) pol protein (3′ end), and envelope protein (5′ end) mRNAs, clone T-7.2 (Genbank Acc. No. M19049.1), see nucleotides 243-261.
ST Crooke, Progress in Antisense Technology, “Progress in Antisense Technology: The End of the Beginning,”1999, 1, pp. 3-45.
Rahman, M. Sayeedur, et al., “Nebularine (9-2′-deoxy-beta-D-ribofuranosylpurine) has the template characteristics of adenosine in vivo and in vitro”, Mutation Research, vol. 377, No. 2, 1997, pp. 263-268.
Loakes, D. et al., “5-Nitroindole as an universal base analogue”, Nucleic Acids Research, vol. 22, No. 20, 1994, pp. 4039-4043.
Ohtsuka, E. et al., “An alternative approach to deoxyoligonucleotides as hybridization probes by insertion of deoxyinosine at ambiguous codon positions”, Journal of Biological Chemistry, vol. 260, No. 5, Mar. 10, 1985, pp. 2605-2608.
Nichols, R. et al., “A universal nucleoside for use at ambiguous sites in DNA primers”,NATURE, vol. 369, No. 6480, Jun. 9, 1994, pp. 492-493.
Metzger W. James et al., “Oligonucleotide therapy of allergic asthma”, Journal of Allergy and Clinical Immunology, vol. 104, No. 2 part 1, Aug. 1999, pp. 260-266.
Stull, R.A. et al., “Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices”, Nucleic Acids Research, 20(13): 3501-3508 (1992).
Monia, B.P. et al., “Selective Inhibition of Mutant Ha-ras mRNA Expression by Antisense Oligonucleotides”, J. Biol. Chem., vol. 2G7 No. 28, Issue of Oct. 5, 19954-19962 (1992).
Pasternak, Gavril W., “Molecular Neuropharmacology”, The Scientist, 10(8):14 (1996).
Research Program—Antisense Technology, Novopharm Biotech—Research Program—Antisense Web Page, http://www.novopharmbiotech.ca/asense.htm.
Akhtar, S. et al., “In vivo studies with antisense oligonucleotides”, Trends in Pharmacological Sciences, Current Techniques, 18:12-18, (1997).
Nyce, J.W., “Antisense oligonucleotides as emerging drugs”, Emerging Drugs, 3:365-375, (1998).
Nyce, J.W., “Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases”, Exp. Opin. Invest. Drugs 6(9): 1149-1156 (1997).
Nyce, J.W. et al., “DNA Antisense Therapy for Asthma in an Animal Model”,Nature, 385(20): 721-725, (1997).
Webb, A. et al., “BCL-2 Antisense Therapy in Patients with Non-Hodgkin Lymphoma”,Lancet, 349(9059): 1137-41, (1997).
Yazaki, T. et al., “Treatment of Glioblastoma U-87 .by Systemic Administration of an Antisense Protein Kinase C-Alpha Phosphorothioate Oligodeoxynucleotide”,Molecular Pharmacol., 50(2): 236-242, (1996).
Farmer, S.G. et al., “Adenosine Receptor-mediated Contraction and Relaxation of Guinea-pig Isolated Tracheal Smooth Muscle: Effects of Adenosine Antagonists”,Br. J. Pharmacol., 95: 371-378 (1988).
Marquardt, D.L. et al., “Aminophylline Exposure Alters Mouse Bone Marrow-derived Mast Cell Adenosine Responsiveness”,J. Allergy Clin Immunol, 78: 462-469, (1986).
Simpson, R. U. et al, “Antisense oligonucleotide targeting against protein kinase C beta and C beta II block 1,25 -(OH)- 2D3- induced differentiation”, J. Biol. Chem. 273(31):19587-19591 (1998).
Chen, CC et al, “Protein kinase Ceta mediates LPS-induced nitric oxide synthesis expression”, J. Biol. Chem. 273(31): 19424-19430 (1998).
Glukhov, A. I., et al., “Inhibition of telomerase activity of melanoma cells in vitro by antisense oligodeoxynucleotides”, Biochem. Biophys. Res. Commun. 248(2):.368-371 (1998).
Banasiak, K. J. and Haddard G. G., “Hypoxia-induced apoptosis: effect of hypoxia severity and role of p53 in neuronal cell death (Antisense to p53)”, Brain Res. 797(2): 295-304 (1998).
Lehenkaru P et al, “Carbonic anhydrase II plays a major role in osteoclast differentiation (antisense to carbonic anhydrase II)”, Exp Cell Res 242(1):128-137 (1998).
Dooley NP et al, “Apoptosis is induced in glioma cells by antisense oligonucleotide to protein kinase C alpha”, Neuroreport 9(8):1727-1733 (1998).
Kondo S et al, Antisense telomerase treatment: induction of distinct pathways, apoptosis and differentiation, FASEB J. 129100:801-811 (1998).
Alahari SK et aL, “Novel chemically modified oligonucleotide provide potent inhibition of p-glycoprotein (an ATPase that serves as a drug efflux pump)”, J.Pharmacol. Exp. Therapeut. 286(1): 419-428 (1998).
Wu Pong, S. “Oligonucleotides: Opportunities for Drug Therapy and Research,” Pharmaceutical Technology, vol. 18: 102-114.
Miller et al. “Gene Transfer and Antisense Nucleic Acid Techniques,” Parasitology Today, vol. 10, No. 3: 92-97.
Stull et al. “Antigens, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects,” Pharmaceutical Research, vol. 12, No. 4: 46j5-483.
I. Milligan et al.;Current Concepts in Antisense Drug Design. J. Med. Chem. 36(14): 1923-1937 (1993).
S. Ali et al.;Adenosine-induced bronchoconstriction in an allergic rabbit model:antagonism by theophylline aerosol. Agents Actions37:165-167 (1992).
S. Ali et al.;Modification of allergen-induced airway obstruction and bronchial hyperresponsiveness in the allergic rabbit by theophylline aerosol. Agents Actions37:168-170 (1992).
S. Ali et al.;Adenosine-Induced Brochoconstriction and Contraction of Airway Smooth Muscle from Allergic Rabbits with Late-Phase Airway Obstruction: Evidence for an Inducible Adenosine A1Receptor. J. Pharmacol. Exp. Therapeu. 268:1328-1334 (1994).
S. Ali et al.;Adenosine receptor-mediated bronchoconstriction and bronchial hyperresponsiveness in allergic rabbit model, Am. J. Physiol. 266:L271-277 (1994).
D.R. Sibley, et al;Transfected Mammalian Cell Lines Expressing the A1 Adeonsine Receptor NTIS Field/Group Codes: 57F, 57B, 57O 90D(Jun. 5, 1991).
Dennis J. U., et al, “Human melanoma metastases is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C alpha”, Cancer Lett. 128(1):65-70 (1998).
Haeckel C., et al, “Antisense oligonucleotide inhibit ur

Affiliated with

Also associated with

Rating

Low adenosine anti-sense oligonucleotide, compositions, kit... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Low adenosine anti-sense oligonucleotide, compositions, kit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low adenosine anti-sense oligonucleotide, compositions, kit... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3557584